Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$2,376 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
1,207,190
CFO
CA$-55.17 Mln
EBITDA
CA$-65.91 Mln
Net Profit
CA$-77.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
InMed Pharmaceuticals (INM)
| -47.5 | -9.8 | -10.4 | -54.9 | -78.9 | -76.5 | -50.8 |
|
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
InMed Pharmaceuticals (INM)
| -79.4 | -93.8 | -60.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches... and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Address: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 Read more
President, CEO & Director
Mr. Eric A. Adams B.S. Chem., M.I.B.
President, CEO & Director
Mr. Eric A. Adams B.S. Chem., M.I.B.
Headquarters
Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of InMed Pharmaceuticals Inc (INM) stood at $ 15,685 Mln as on 31-Mar-25
The share price of InMed Pharmaceuticals Inc (INM) is $2.49 (NASDAQ) as of 20-Jun-2025 16:00 EDT. InMed Pharmaceuticals Inc (INM) has given a return of -78.92% in the last 3 years.
InMed Pharmaceuticals Inc (INM) has a market capitalisation of $ 3 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of InMed Pharmaceuticals Inc (INM) is 0.43 times as on 18-Jun-2025, a 88% discount to its peers’ median range of 3.48 times.
Since, TTM earnings of InMed Pharmaceuticals Inc (INM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the InMed Pharmaceuticals Inc (INM) and enter the required number of quantities and click on buy to purchase the shares of InMed Pharmaceuticals Inc (INM).
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Address: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8
The CEO & director of Mr. Eric A. Adams B.S. Chem., M.I.B.. is InMed Pharmaceuticals Inc (INM), and CFO & Sr. VP is Mr. Eric A. Adams B.S. Chem., M.I.B..
There is no promoter pledging in InMed Pharmaceuticals Inc (INM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| InMed Pharmaceuticals Inc. (INM) | Ratios |
|---|---|
|
Return on equity(%)
|
-181.39
|
|
Operating margin(%)
|
-177.62
|
|
Net Margin(%)
|
-268.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of InMed Pharmaceuticals Inc (INM) was $0 Mln.
$-0.02
(
